and david ricks from eli lilly, in the 8:00 hour.nd microsoft, starbucks and a lot more. >> can i tell you something exciting just for us because we like these types of things. david ricks is coming on, right? so the -- i can't believe this, but the estimate for lilly, 1.47. >> okay. >> zepbound. the weight loss drug. >> right. >> i think revenue probably rose to 12 billion from 9 billion supposedly. >> okay. >> 1.47. what did they earn last year? ten cents. so the net income last year was $95 million. this year, it's going to be 1.3 billion. it's a 15% price gouging increase in this pharmaceutical -- they had a charge last year of $2.8 billion for in progress, research and development. so it goes from ten cents to 1.47. senator warren and senator sanders, i'm just giving you some stuff here. you can use this and not explain it. and you can, once again, make this point that these companies are gouging and profit mongers. this is the perfect opportunity. that's what she did last time. she did it with kraft. so you've got a year-ago fi

the stock pick at the moment is eli lilly. why do you like it so much?tting skinnier with the drugs it's selling to people. stuart: you're funny. >> we had to try. this is a company selling off on a bad quarter as in the expectations a bit lower, but sold over $1 billion worth of zep bound without a single dollar of advertising and glp1s and weighted loss drugs are the drug of the future and next humera and was for all sorts of autoimmune dis diseases and it'e lie lily's -- eli lilly's leaders and get in and buy the dip and winner in the race between eli and nov novo nordis. stuart: after a painless injection, pills win. next one is inodata. >> this is a pick and shovel way to play and ai with contracts with five of the seven in the mag seven and growing earnings at 60% plus right now and great way under the radar and small cap company playing into the trends of getting more attention and it's going for ai in a while. ai sectioners going through this countless times. stuart: is the money there to build ai? >> not a single solution that provides that and

we are diving into what investors are expecting from eli lilly's telast quarter.ar. ♪ ♪ ♪ i'm gonna love you forever ♪ ♪ ♪ c'mon, bear. ♪ ♪ ♪ you don't...you don't have to worry... ♪ ♪ be by your side... i'll be there... ♪ ♪ with my arms wrapped around... ♪ >>> welcome back to "fast money." eli lilly on deck to report tomorrow, investors looking to see how strong growth will be for the pharma giant's glp-1 drugs. lilly shares hit an all time high in late august but have been range bound since then. competitor novo nordisk which had been tracking with lilly earlier this year has been under pressure lately, up 8% so far this year. this could be pivotal for this trade, lilly of course has the alzheimer's drug as well in the pipeline. >> we've looked at novo and said huge support level that it breached and actually trades worse now than eli lilly. they seem to have found a home around 885, 89, looks like novo has room to the down side. i like limby more than novo at these levels. >> the competition and i use that sort of broadly because nobody has the money in the man

you've heard me talk about the glp-1 and i always tell you to get eli lilly. this gives you something you can't find anywhere else but because it is a pure play and the stock has gotten expensive at an all-time high up 50% over the last year it is pretty pricey. given that wall street only expects them to earn at a 10% clip, if they are growing at 10% i would not be willing to pay more than 20 times earnings for stock. then again, maybe somebody like pepsi will acquire them to compete in the space. it does explain why the stock could be up so much. here's the bottom line. bellring brands has a great story. if you like this one please wait for a pullback before you pull the trigger. maybe coke will make some comments about protein and take down the entire group. either way, put it on your shopping list and wait for a selloff to give you a better price. once again, i think a fabulous viewer for a fantastic idea. amy in pennsylvania. >> booyah, jim. how are you doing? >> i am absolutely awesome. me and my husband watch you all the time. >> fantastic. i hope i can

>> my stocks are eli lilly, costco, apple, dupont, eaton. >> you have eli lilly one of the premier stocksera. we like these guys because they have been at the forefront. dupont is splitting into three companies run by a terrific group of people. that will bring more value than they have now. costco, we are learning they may be having a netflix moment. they will really start checking cards and cracking down on passwords. apple, own it don't trade it. we have tech, retail, diversified manufacturer, company splitting into three and a drug company. you are person -- perfectly diversified. thank you. you rock. what can i say? you have four cents. let's go to tony also from florida. >> i want to thank you for doing this type of thing, diversified. a lot of us don't have stock in the club but it really help us us out. >> i'm so glad you mentioned that. i want the club specifically to be teaching so people's pick their own stocks. i can't keep track of all of them. let's go to work. >> my first one is with a.i., probably dell. the next one is pfizer, then we have amd, home depot, then we have con

that includes of those for eli lilly and ozempic and others.lilly and novo notice rely on norfork, the company shut down by the strike. they said that it is now going to use airfreight with shortages while eli lilly has not said but the contingency plans are. analysts say in the short-term the weight loss drug should be widely available, if this drags on, it will change dramatically. stuart: lindsey davis compared tim walz's debate performance with another disastrous event. watch. >> reminded me of the june 27th debate when kamala harris said of president biden it was a slow start but a finish. there were uncomfortable moments. stuart: that's not good for the harris camp. brian kilmeade takes it on next. ♪ ♪ when a tough cough finds you on the go, a syrup would be... silly! woo! hey! try new robitussin soft chews. packed with the power of robitussin... in every bite. easy to take cough relief, anywhere. chew on relief, chew on a ♪ robitussin ♪ we really don't want people to think of feeding food like ours is spoiling their dogs. good, real food

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 2030, 2035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that's often not mentioned in, say, the political deb

is here a huge properly good this week when analysts are getting really excited about one up of eli lillyiple regiment that they're working on. viking said hold on we have a quadruple regimen than the oral pill, shot. they're going to four blades. the one upping, they are innovated in the space. >> you said they're going to a pill. >> there is a pill and a monthly shot instead of the weekly shot in the works this can help with the weight loss magnitude according to william blair this will up the ante and more weight. >> what does it mean for lillian novo. >> i was interested in the clip eli lilly only down 2% clearly they are the 800-pound gorilla in the space not too concerned about the competition but the field is widening. >> enough for everyone to make money. >> i'm looking for a stock pick you say you like schneider and i love pretzels but were not talking about the pretzels. >> of honeywell and even trades about 26 times 115% i been doing very well good momentum and like j.p. morgan puts it the simplest cleanest best way to play a.i. electrification in all the trends. snyder electri

. >>> still ahead, eli lilly ticking higher. ticking higher.♪ ♪ e details are coming up. - [narrator] we just signed the lease on our third shop. my assistant went to customink.com to get new uniforms with all the locations. he fuploaded new art,ts,p■l and had boxes sent to all the shops. custom ink makes it so easy. get started today at customink.com. what is cirkul? cirkul is the fuel you need to take flight. cirkul is the6 energy that gets you to the next level. cirkul is what you hope for when life tosses lemons your way. cirkul, available at walmart and drinkcirkul.com. when you're looking for answers, it's good to have help. because the right information, at the right time, may make all the difference. at humana, we know that's especially true when you're looking for a medicare supplement insurance plan. that's why we're offering "seven things every medicare supplement should have". it's your free, just for calling the number on your screen. and when you call, a knowledgeable, licensed agent-producer can answer any questions you have and

when eli lilly comes to market, they come with everything necessary to develop the market. are benefitting from that significantly. >> in other words, do you think these drugs are a step beyond what was previously achievable by medications on the market, or are people going to realize maybe yours or maybe there's others out there that have some benefits as well that are working and this isn't the weight loss drug pill or craze of decades past. >> this is the latter, right? so in every chronic disease that we've ever controlled as a society, we have had multiple medications in the class. right now with anti-obesity, we have llp-1s, i my product and others. so we need five or six medications to get control of this disease. it's 100 plus million adults. >> can it treat things like other addictive behaviors and problems like we're finding with some of the glps? >> we have a phase three ready program we're negotiating with the fda right now to take a version of it into clinical trials. >> if you stop taking it, does obesity come back? >> it's a chronic disease, and if you stop t

and it's a window which novo nordisk and eli lilly argue. look, we develop these drugs, we should make some money in that period. we should benefit. i agree with them, but i would argue they don't need to make quite as much as they currently do. we could regulate them. you know, at the moment, novo nordisk is now the most profitable company in, the whole of europe. so i think we should be, you know, prioritizing, getting the drugs to people who need them, not least because by many measures, obesity is the killer in this country. professor mander at harvard, who the food label that's on all food the united states sold in the us. so explain to me, presented with his calculations that obesity and food related illnesses. kill 678,000 american boys every year that's more all the american soldiers who died in all the wars of the 20th century and indeed the war in this century and. i mean, that is a staggering toll. that's, you know, not far off having covid every year. the covid pandemic, every year. right. and that stock, we shouldn't accept this

what that data means for the darling, eli lilly and know vo noer tis after this.ial advice from ameriprise can do more than help you reach your goals. -you can make this work. -we can make this work. it can help you reach them with confidence. no wonder more than 9 out of 10 of our clients are likely to recommend us. ameriprise financial. advice worth talking about. (♪♪) (♪♪) what took you so long? i'm sorry, there was a long line at the thai place. you get the sauce i like? of course! you're the man! i wish. the future isn't scary. not investing in it is. nasdaq-100 innovators. one etf. before investing, carefully read and consider fund investment objectives, risks, charges, expenses and more in prospectus at invesco.com next on the red carpet we have gina costa... looking simply stunning... with this season's hottest accessory. -[ cellphone vibrates ] -oh, what's this? she's opening her fidelity app... to buy that stock... for exactly the amount she wants... no fees or commissions... what will gina do next? gina has roller derby at 6:00 pm. i'm there. get starte

eli lilly, they reported this morning.their weight loss drugs missed expectations, and the stock concern well, now it's down 4%. earlier it was more like 10%. >> maybe they've already picked off some of that low hanging fruit, right? if you've got 35% body fat, maybe you're already on a glp-1. the demand profile's a little different when you get down to 25% body fat and when you go all the way down to 15% body fat where someone's just doing it for cosmetic purposes, that presents a challenging landscape. eli lilly said compounding pharmacies are not a problem. i've talked about this in the past, i do think they're a problem. i'm not 35% body fat, and if i wanted to buy a bottle of this stuff right now, i could have it delivered to my doorstep without a prescription in probably 22-3 business days -- 2-3. i do think that's a problem for not just eli lilly, but anyone else who's in the market. stuart: fair enough. starbucks, they're looking to be in a turn-around situation. they report after the bell today. what are we going

. >>> coming up, big plans for eli lilly. the pharma giant investing billions in a new research hub how it will impact their drug pipeline, and what the ceo had to say, next. >>> plus, a billionaire blend. bill ackman roasting starbucks -- you almost spit out your candy bar, tim -- even as brian niccol looks to turn things around. why he's so bitter on the name, ahead. ahead. don't go with confidence. no wonder more than 9 out of 10 of our clients are likely to recommend us. ameriprise financial. advice worth talking about. ♪♪ anywhere. "fast money" is back in two. ♪♪ beaches jamaica sale is now on. visit beaches.com or call 1-800-beaches. (cheerful music) (phone ringing) beaches jamaica sale is now on. (7?uo cf. the bootstrapper. the bootmaker. yeehaw [narrator] but many do have something in common. we all trust schwab with our wealth. [narrator] thanks to our award-winning service, low costs and transparent advice. every day, over a million multi-millionares trust schwab with more than two trillion dollars of their wealth.

eli lilly down 8%, and carvana, as part of the "three stock lunch."power lunch" will be right back. ♪♪ ♪♪ at state street, we know everyone's trying to get somewhere. ♪♪ take the next step toward your future, by investing in the dow with dia. getting there starts here. >>> its time for a deluxe three stock lunch. it's the thick of earnings season. let's get three names and victoria green is here with us, a cnbc contributor. victoria, welcome to you. let's start with caterpillar, shares off the worst level of the session. before we get your trade, let's bring in seema mody with all the details. >> kelly, this was significant the first tine of a year-over-year decline in four years. inventory levels remain too high, raising concerns that cat won't be able increase prices. barclays says it's a red flag for the bears. analysts blaming higher rates for the slowdown, but shares did bounce off the lows after the ceo said the company is building more capacity in engines for data centers, saying data centers relike on cater pell hearts for backup generators. t

we get results from mike s, eli lilly, microsoft, coinbase and etsy, just a few reporting. >>> and markettting set for mega tech as the nasdaq comes off the record high. joining me, amy silverman. good to see you. >> good to see you. >> let's talk about what you're seeing in the options market when it comes to the mega tech and mag seven, what are investors seeing? >> yeah, it's incredible to think about everything that's going on this week. look, the big difference, frank, between the first half of this year and the second half is we were incredibly exuberant on the options side. people had a lotauot of fomo, ww a lot of call buying. you're seeing less of that now. it's more positioning that people have gotten long in names they've gotten long. what we're seeing in the deriv t derivtives markets. >> people are bullish when it comes to mega tech? >> right. >> can i get the word of the day, nasdaq hitting a record close, first since july, how do you see today shapingup. >> well, my word of the day is overhang. the reason it's overhang, when you think about today, when you think about the n

eli lilly cut. amd, you could argue -- eh. this company was even stronger than alphabet, why?that comment. they have become a must-buy for almost every cpg company, david, all the consumer packaged goods companies. that are in -- there are seven verticals that are up 50% on this thing. i think that literally, there are people, david, who start their day and keep their day on this. daily average users, 97 million. david, they made money and not in that gap -- nonsense -- i almost used a word that would be censored. they made it the old-fashioned way. >> you know, it is a stunning move here for this stock price since the company went public, and there were certainly no shortage of questions, given it was, what, almost 20 years from inception to going public. they had rarely, if ever, really been profitable. and yet, boom. and it's not just because they allow the large language models to run over their data. >> which this is raw user power. there are these verticals that you can reach that nobody else has. look, my daughter beat melanoma, so there's a -- there's like a family of

eli lilly falling. >> reporter: scott, mounjaro is coming up short. 1 drugs are so crucial for lilly. trimming the full year sales forecast by $600 million. that comes one quarter after raising it. >> we are taking a little bit off the top of our guide because during the quarter i think we cha changed an assumption. we changed the assumption we should start promoting and launch being sooner in the u.s. and other markets. we pushed some of that out into q4 because of customer service levels. we want to make sure people when they get a prescription can if i recall it. >> now rick is saying this is not a supply issue nor is it a demand issue, rather, he's saying this is actually something called channel, destocking. basically wholesalers have plenty of product and they're working through that instead of buying more. now of course this is raising questions because there is so much demand as we know for these products. a lot of questions today about what that dynamic looks like and what we should expect going forward, scott. >> angelica, thank you. the late

microsoft and meta report later this afternoon, but eli lilly, uh-oh, it's going the other way. its profit outlook disappoint, and the stock is way down. it is off 10%. earlier this morning the first reading on the economy. in the third quarter, expanding rate of 22.8% -- 2.8%. the economy slowing a little, the consumption indicator rose sharply. the dow down about 85 points, nasdaq is down 23. let's see, the nasdaq -- was with doing well with help from google but it's slipped into the minus column. bitcoin's record is $73,798, this morning it's $76,4 -- 72, 4. what was that? 71,4. got that. interest rates, on the consumption number rising. the 10-year treasury over 4.25. % -- the 2-year, 4.14. gas, no change, $3.13 a gallon. diesel up one cent, $3.57. gold really close to $2, 800 an ounce. on the show today, china hacks the phones of trump and family members. reportedly, they listened the conversations. headline, ukraine is now struggling to survive, not to win. that as north korean if troops are approaching the battle field. we will ask if it is biden who loses ukraine. and th

the shortages of two weight loss drugs made by eli lilly has been resolved, according to the fda. the diabetes medication mounjaro and the weight loss drug rebound are no longer on the agency's shortage list. but consumers may still run into occasional local shortages for a while as those drugs move through the supply chain. >> an influx of so-called leaf peepers in the colorado rockies has some locals now demanding action. they say large crowds of visitors wanting to view the fall foliage are ruining everything by clogging mountain roads, littering and parking illegally. one person saying it took over two hours to go one mile sounds like manhattan police say they are going to increase patrols in the area, and one resident called the visitors leaf peeping dingdongs. >> well, you know, rhiannon, those leaves aren't going to post to instagram themselves. exactly. you got to get out there. you got to take the picture. didn't happen on its first. no, no. people want to enjoy this. >> they want to enjoy the fall. fall is the most beautiful season. >> get over it. colorado, right. that'

we got a lot more ahead including our exclusive with the drug company eli lilly.e trying to fight the rise of counterfeit medications. >> george: right now an abc news exclusive in the case of lindsey shiver, accused of plotting to kill her estranged husband. this morning we are hearing from her ex-boyfriend and alleged accomplice. eva pilgrim is here with the story. good morning, eva. >> good morning, george. that ex-boyfriend telling us there was no plot, no plan to kill anyone. this morning he's speaking out about what he says really happened. this morning the georgia mother of three accused of plotting to kill her estranged husband in the bahamas back on the island and in court. abc news following her return to nassau for a pretrial hearing exclusively speaking to her ex-boyfriend and alleged accomplice. >> nobody ever wanted him dead. >> reporter: he's accused of plotting to murder shiver' husband robert. investigators say he even enlisted the help of a friend. but bethel said they never planned to kill anyone. >> i'm definitely not guilty of conspiracy to co

eli lilly shares down 7%. alphabet kicking off tech earnings, reported a double beat with a.i. revenue by 35%, $11 billion in that cloud revenue. stock is up 6 and-a-half percent right now. we are going to hear from microsoft and meta after the bell tonight. and then of course there's amazon and apple tomorrow night. these could be market movers coming up, particularly apple. what are your thoughts on earnings season so far, particularly in big tech. >> so the alphabet earnings is pretty exciting. i'm someone who is on the record as being a major bull of nvidia. if you listened to the call, the ceo talked about how generative a.i. and a.i. tools used for search is increasing interest and more search activity on the google search engine and we like seeing that if you're an nvidia bull because that means that you're starting to find ways to monetize a.i. these companies have been investing and so this is really bullish if you're on the a.i. train in any way, shape or form. he also talked about the cloud which again really benefits some of the semis and alphabet is not seen necess

and eli lilly's mounjaro and zepbound.dly popular weight loss drugs known as glp-1s. the ozempic we brought from laver beauty cost $219, while real ozempic goes for nearly $1,000 for a month's supply. the company's website in corporate documents claim the operation is located in boulder, colorado. but the ozempic we ordered from laver beauty was shipped via dhl from this office building in china, off an elevator and behind this unmarked door, right to us at cnbc headquarters in new jersey. let's open it up and see what we have. plain cardboard box. it doesn't appear to have any refrigeration. though it's supposed to be refrigerated. this might have been a refrigeration pact. it dud say ozempic on it, 1 milli milligram. and here's the pen. looks like the real thing. let's see what's inside. was this real ozempic diverted to the u.s. or a fake? and why did it come from china, when the company has a colorado address? we'll answer that question, but first, our investigation brought us to the uk, where hundreds of counterfeit o

first of all, eli lilly. why do you buy it and where do you think it's going?ah, that's right. eli lilly's a name we like, one, fda just gave approval on a dermatitis drug, which is a big deal. again, we're sitting close to the all-time highs for the stock, i can see a good 10% upside for the stock. in this environment if i can get a 01% pop between now and the end of the year, that's pretty good, stuart. tooth study you also bought micron. why? >> yeah, that's right. we're very bullish on semiconductors right now. if you look from a valuation standpoint, a lot of the time we forget about micron. mu's trading about a third of the valuation of nvidia. >>. i think this stock can pop 50% from here, and i don't say that lightly. i think there's big upside in this name because investors are sleeping on it, and it had a bill selloff, about 20%, from its highs so far this year. stuart: i one last one, amd. advanced micro devices. >> same thing, semiconductor name if. it's a name we had money to worw what? more because of the gaming console sales were down. i think tha

buzz kill on eli lilly.e company missed q-3 earnings estimates. they cut full-year guidance on disappointing numbers for its block buster weight loss drug. still, our next guest sees a prime buying opportunity. jared holz is health care sector strategist at mizuho. >> thank you. >> a lot of questions as to what was behind the miss in the third quarter. that goes -- to answer that question is to understand why lilly would be a buy. so, do you have an answer when it comes to the company's line that wholesalers were destocking in the quarter? >> well, i don't think we really have enough information to, you know, completely understand the dynamics that happen in the third quarter. i think we're really only into the third full launch of zepbound, and the second full year of mounjaro, so, it's a little bit tough to go back and search for a trend that kind of makes sense, that leads us to a definitive answer here. some of the destocking they talked about, i can see that based on what they said in a prior period abo

. >>> when we come back, the shortage of eli lilly's popular weight loss drug ends.apid relief at 4 weeks. tremfya blocks a key source of inflammation. at one year, many people experienced remission...a na and some saw 100% visible healing of their intestinal lining. serious allergic reactions and increased risk of infections may occur. before treatment, your doctor should check you for infections and tb.c is te i your doctor if you have an infection, flu-like symptoms or if you need a vaccine. healing is possible with tremfya. ask your doctor about tremfya today. ♪ my life is full of questions... how don townan an aioli stain? thof them. —do crabs have eyebrows? —except that one. for all of life's laundry questions... it's got to be tide. is coming to the u.s. upset stomach iberogast indigestion iberogast bloating iberogast thanks to a unique combination of herbs, iberogast helps relieve six digestive symptoms to help you feel better. six digestive symptoms. the power of nature. iberogast. mopping is hard work, but then i tried the swiffer powermop. it has a built-i

el ingrediente activo de montjiro y medicamentos para la diabetes y la pÉrdida de peso de eli lilly. obtenido por los fiscales del condado de los Ángeles, estaba tan molesto por la forma en la que un entrenador de fÚtbol de ucla estaba disciplinando a su hijo en 2015, que fue a la oficina del entrenador y peleÓ con Él, estrangulÓ brevemente a un pasante y puso a otro miembro del cuerpo tÉcnico en una llave. aunque fue arrestado bajo sospecha de agresiÓn con un arma letal. amenazas criminales y agresiÓn en el incidente. en Última instancia, no fue acusado de ningÚn delito. un marinero ruso es rescatado tras pasar 67 dÍas en alta mar y ademÁs muy dÍas en alta mar y ademÁs muy ce ♪♪ ¡hola señor ramirez! ¿cómo está? ¡muy bien! gracias. mira, ¿hay alguna opción más económica para mi nueva receta del medicare? ¿medicare? pero si parece de 45? [ambos se rien] creo que sí. ♪♪ ¡sí! parece que hay otra opción. podemos llamar a su doctor y su receta estará lista para la próxima vez. esto no es solo ayuda con una receta de medicare. esto es el tipo de ayuda más humana. walgreens. ¡tenemos los me

eli lilly blamed inventory issues for the mess.fox and mlb are looking like the winners. game three averaged 13.6 million viewers, beating monday night football. it is the most-watched world series in years, averaging 14.4 million viewers per game according to fox. in japan, this humans is averaging almost 16 million viewers, even more than in the u.s., equivalent to 12% of the country's population. that is were brief. jonathan: thank you for this morning. we will set you up for the day ahead and look ahead to big earnings touch base with ed ludlow in just a moment. ♪ jonathan: the equity feeding a touch over the past few hours, slightly negative on the s&p 500 with the open 36 minutes away as we count down to the opening bell. meta and microsoft reporting after the closing bell thursday. results from apple, amazon, intel. we'll also get a boj rate decision and another round of jobless claims and core pce on friday. the people's report, the u.s. presidential election on tuesday followed by the fed rate decision just two days later.

eli lilly -- >>> eli lilly is suing -- you are always weird about that.interesting. >> the whole thing. myself. i do. >> there, i'm with you. eli lilly is suing three medical spas and online stores for selling copycat weight loss drugs. the vendors in question sold products claiming to contain zepatide and dissolvable tablet. zepatide is the main ingredient in eli lilly's zepbound. how many words can you create? >> roll it back. i have to look at it. >> don't do that. more viewer problems for andrew. >>> when we come back, mike allen will join us including the musk's $1 million per day give away for voters. >>> and chmu more on the tentative deal to end the strike at boeing. questions whether the union will actually vote for this or not. "squawk box" will be right back. i doesn't make you a rock star. it kinda does. you are not rock stars. (clears throat) okay. most of you are not rock stars. oooh. data driven insights, and large language models. oh, that's so rock roll. it is, right. he gets it. yeah. >>> welcome back to "squawk box." over the weekend, b

eli lilly está demandando a varios vendedores en línea y spas médicos por vender productos que afirmanoducto a pacientes sin receta médica. y según una encuesta de bankrate, más del 80% de los viajeros que vacacionan dice que están cambiando sus planes debido a la inflación para la temporada de fin de año. eso representa un 83% de los que planean viajar en avión o alojarse en un hotel o airbnb. el aumento de los precios ha provocado cambios en comportamiento, ya que aproximadamente 1/3 de las personas encuestadas piensa viajar por menos días de lo anticipado y otro 30% está buscando alojamientos y destinos menos costosos y manejar en vez de volar. financieramente, se espera que el costo promedio en vuelos para acción de gracias sea de alrededor de 925 $ y que podría aumentar hasta 1.100 $ para diciembre. yo soy silvana henao y este es tu informe cnbc para telemundo. los niners quedaron con récord negativo tras una nueva derrota ante los schiff y al conversar con los fieles de la bahía. además de preguntarles por el partido del domingo, también queríamos conocer su visión sobre la actua

and also we have heard from eli lilly, the drug company, that they are going to invest £279 million andweight loss drug trial with a national health service here. i think the government feels it is going well. what is the government promising in return? i think it is about stability. let's not underestimate the incredible political instability there has beenin political instability there has been in this country over the last eight years. for prime ministers, six chancellors of the x. we now have a labour government with a very big majority that is likely to be in office for the next five years. that is what the international investors are looking for. that is why they are talking about now be the time to invest because of what they hope will be a significant stretch of stability here. zoe. stretch of stability here. zoe, i am stretch of stability here. zoe, i am sure _ stretch of stability here. zoe, i am sure you _ stretch of stability here. zoe, i am sure you will _ stretch of stability here. zoe, i am sure you will keep - stretch of stability here. zoe, i am sure you will keep us -

iis drug company eli lilly is investing £279 million, but it's come with a warning.n the uk is on _ warning. i think the difference in the uk is on your— warning. i think the difference in the uk is on your own _ warning. i think the difference in the uk is on your own now- warning. i think the difference in i the uk is on your own now separate from europe, it's a relatively small market from most multinationals and certainly for americans, so something needs to be different to make it interesting.— something needs to be different to make it interesting. growth might be the number one _ make it interesting. growth might be the number one priority, _ make it interesting. growth might be the number one priority, however- the number one priority, however ministers also want to strengthen workers' rights and raise taxes. how it all fits together is not yet clear. zoe conway, bbc news. we're joined by our political correspondent hannah miller. hannah, how important is this for the prime minister? this today is a display, a showcase for those in the room and those beyond.

. >> anthony, final word on eli lilly? buy it sell it? own it? take out options?u own it here, i call itted nvidia the healthcare sector. and certainly a poster child for class 1 stocks. and they're just increasing capacity and innovation. the only sure is valuation reflects a lot of that at 40 times plus earnings, so what we advise the clients is continue to own it, but think about managing the position size given how much it's moved up and what it represents in the portfolio. >> i take your point. >>> any quick final comment? >> i think we're seeing it every day with the election, and we're probably going to have elevated volatility into the election. you know, what's happening on the shoremen strike is a factor and possibly a political issue. >> anthony, thank for your time today. we appreciate it. >> thank you. >>> let's get over to julia boo boorstin. >>> president biden told reporters this afternoon he would not support a strike on iranian nuclear sites in retaliation to the ballistic missile attack yesterday on israel. they agreed during a conference call t

. >>> the fda will recover a decision to bar drug compounders to sell eli lilly's weight lost and diabetess. >>> berkshire hathaway is increasing its stake in sirius xm. it bought more than 3 million shares last week and holds a 32% share in the satellite radio provider. >>> and spacex made a dramatic first catch of the more than 20-story tall booster. a major milestone to the company's goal of making starship a fully reusable system. >>> it is all about earnings season and four remaining big banks and citi and bank of america and goldman with regionals and super regionals as well as united health and johnson & johnson reporting. risk assets putting in a good performance with the s&p with a fifth straight week of gains. banks powering higher. the kbw index jumping 3% on friday. let's bring in matt orton at raymond james asset management. matt, good morning. >> good morning, frank. great to see you. >> matt, what's your word of the day? >> my word of the day is dispersion. we have a big week for earnings and it will only pick up from here. i think the trend we have seen over the past couple

then eli lilly. one of our best picks. this morning a note was put out talking about the impact of these drugs on the food stocks. all of the analysts and people in the food industry, they say it is going to impact the food companies negatively. when we walked around the floating platform in the gulf of mexico i picked up on every machine i saw. the predominant one was caterpillar which makes solar turbines that we call turbines that would power a great deal of activity. the chevron ceo reminded me that it came from that.'s reports could be very strong. i just don't know if it will be strong enough to move what has been an incredibly hot stock. i would not be surprised if they give up some of that. it's up 30% of the year. then we have meta and microsoft. they had a stellar quarter. i think they could do it again. for microsoft, lets talk about how copilot may not be as strong as we thought. somehow they have to put that story to rest. here is one that makes a big splash every time. it's called booking holdings. it has bee

30 or so of 2022 chatgpt rolled out the stock market rally all about two things ai, and ozempic eli lilly there are clear winners and losers, what do you make of -- case market has been led by two major themes what do you make of that now that there is maybe flame around intelligence. >> i think on technology front a revolution a j current companies have to spend money from capital expensive standpoint will potentially impact margins i think realization what it is going to take to realize back end is kind of hitting investors although i still think overtime that will prove a wise one, i think part of the story, though, what is going to happen is the broadening of the market. so what is driving that two things number one the valuation of the 493, the magnificent 7, also broadening earnings story this quarter q we think 8 of 11 sectors are going positive year-over-year earnings growth by first quarter of 2025 we think all 11 the inflection point hit four quarters ago the fifth consecutive quarter good year-over-year growth i think if that continues you will see a broadening as you started t

then there is the favorite eli lilly. here is a stock that has been almost as hot as nvidia. given how much it's run into the quarter we needed to see some extraordinary numbers from the revolutionary drugs for diabetes and weight loss and we needed them to raise the forecast dramatically. we got nothing like that. instead, it was a real with. the explanation was totally opaque. i'm still trying to figure out what happened. too much supply, too little demand? talk about an unhappy forecast. my mom was always encouraging and thought i was really smart. she would say, jimmy, if you don't understand maybe it's not understandable. i am invoking that role in this one. the shortfalls are the ones that management simply refuses to acknowledge either because they are in a state of denial or they are full of it. that was the conference call from wingstop. every quarter they give a dynamite set of earnings and forecast but today they had same stale -- sales and did not even mention the earnings shortfall. the only thing wall street hates more is when they try to pretend they missed it.

. >> i don't love novo nordisk and prefer eli lilly and these are ppeptides and heart disease, sleepea and indications of canser and doesn't surprise me we're finding it could cure -- or help slow the progression of alzheimer. stuart: can do all this. that's great. >> looking at biology, it makes sense and you're addressing obesity and downstream negative health affects from diabetes and obesity that's resolving. stuart: thanks, lou. juul, j-u-u-l, that's a vape and receiving payments from a 300,000 class action lawsuit and some are sharing the news on social media. what are tay say -- they saying on the video? >> some claim they didn't know there was a class action lawsuit and surprised when the money hit their venmo accounts and look at examples of the tiktoks folks are making. >> i received $1100 in the juul class action lawsuit. >> your money is probably in your bank act right now. >> $6,000 is a ton of money. >> probably going to use it to buy nor juuls. >> there's an entire genera of tiktokers from simple celebrations and explainers how this all went down and one of these came

>>> eli lilly making a multi-million dollar bet to keep up with the growing demand for its weight loss peebles is live in indianapolis with more. good morning, angelica. >> good morning, carl. that's right, we are here in indy at one of lilly's research lapse. this is the place where zeptide was made. this is a really important area for the company, of course. they have a lot more in development. we sat down with ceo dave ricks yesterday about what's next, here's what he had to say. >> currently, lilly has 11 pipeline projects in obesity. all with sort of different modes of action or different modes of delivery. oral is a big need, of course. multi-modal, so it's different than other glp-1s. we have dual acting and triple-acting drugs with multiple mechanisms to have more potent effects. >> now, a big piece of this investment in going forward for lilly is figure out how to make these medicines. they're really complex, and that's why the company today is saying that it will spend $4.5 billion to open gnaw center about 40 miles northwest of here, that will focus on r&d manufacturing. tha

we will hear from caterpillar along with eli lilly later in the morning as well. get the numbers, starbucks "after the bell", oil giant exxon mobil coming out on friday. a big week for earnings, the fitz-gerald group and to bulky fitz-gerald, good to see you, thank you so much for being here, your thoughts on the earnings season so far, any takeaways at the google quarter as well. companies put up good numbers if they got their stuff together companies that don't are getting punished rightfully so i was thrilled to see what google did particularly from the a.i. and enterprise which we talked about very early on people looked at me sideways when i said this is going to be a big deal, here we are. maria: does alphabet corridor last night and the surgeon revenue around cloud nai, does that give you any indication of what were going to hear from the others a.i. linked companies. >> cloud and a.i. is where everything is happening and that's where you want to be any company focused on cloud or a.i. and increased computing power and more efficiently nai for obvious reaso

if you look at eli lilly yesterday not great demand for glp-1 definitely an underwhelming quarter foren you start to see with nai clear winners and losers. you have nvidia with insane demand with their chips, amd not so much, meta that did not do that well, also but did do well, maybe the whole a.i. rising tide lifts all votes. are you concerned at all about the future of the market driving themes over the course of the next year. >> i'm definitely more concerned about ozempic, that theme versus the a.i. theme. ozempic theme is a physical theme, there is a finite market for glp-1's and the regulatory capture that goes on in the battle between the compound in the manufacture is going to go ahead and happen in there may be folks in washington, d.c. that effectively decide the winner of the battle at the same time battling the fact that there's a cap on revenue that will come from the stream. a.i. stream is exponential i want say limitless but less larger than a physical product. were still in the early days of seeing, in fact, jay i can go ahead and capture these with overall market wit

etf traders will be able to buy an etf that goes longer coinbase, shorts wells fargo come along eli lilly shorts yum brands. the idea is that there are two stocks in each funds and they are supposed to be inversely correlated. you bet against one and short the other. sonali: not your average hedge fund trade. emily: it's not. i don't think that there is any hedge fund out there doing the weight loss versus snack trade. but it is a funny idea to think there is demand out there. we know that derivative based etf's have been wildly popular. we have seen 160 derivative based funds launched this year and that could mean anything. it could be a buffer etf that uses options to protect against downside losses. it could be a yields-based strategy using some type of options a strategy to bring in more income. we haven't seen many products out there that do this kind of pair trading come along one stock, short the other. we will see if they get approved and if there is really demand for these. sonali: it is seeing how it trades aftermarket to see if people are actually on board. what are critics say

jess: health care has pair declines as well as eli lilly after its earnings call this morning becauseaid demand for the obesity drug was not as bad as what investors were thinking. you are seeing the stock pair those declines down after dropping as much as 10% this morning. hooking under the hood at other individual shares that are moving, looking at reddit because we had the sales outlook for the current quarter beating those expectations. surging close to 39%. on pace to close at a record high after it went public in march. snape is benefiting from what happened with the ad revamp. heinz unfortunately when you're looking at what is happening with its earning results, it tempered its outlook for growth when it comes to this year. anticipates growth to be not as high for next year. cannot forget chipotle. you are seeing that stock pressure down over 7% after was -- there was a high bar to meet expectations. with under a week to go ahead of the election, djt volatile after it had five separate halts earlier this month. down closer 20% now. if you look month to, closer to 160% to that w

in july, they both wrote an op ed criticizing eli lilly and novo nordisk for the high cost of their weights drugs. >> the new ceo of starbucks is calling for a business strategy overhaul, as the company continues to battle a slump in sales. the world's largest coffee chain disclosed today in missed earnings expectations for the fourth quarter, seeing steep setbacks in some of its biggest markets, the wall street journal reports. that includes a 10% drop in u.s. transactions and 14% drop in china. they also suspended financial guidance for the next fiscal year. starbucks already lowered its sales expectations twice this year, prompting ceo brian niccol to say they need to fundamentally change their strategy. >> for so many fall favorite season of the year. and perhaps this is why. get a load of this sunset over san francisco this evening. what a gorgeous view. heather gregg, are you seeing this? it's gorgeous sunset about a half hour ago and wow, that is a nice sight for sore eyes. let's talk about storm tracker two here. we do have an active scene, but it's not here in the bay area. we are